AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22992307 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein pulse feeding (PD group, n=30), 72% of dietary protein (1.31 g/kg weight/d on average) consumed in one meal at noon.
Number of subjects: 66
Study 22992307 — intervention group
Group type: COMPARATOR
Intervention: Protein spread feeding (SD group, n=36), dietary protein spread over four daily meals.
Number of subjects: 66
Study 22992307 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein pulse feeding (PD group, n=30).
Number of subjects: 66
Study 22992307 — intervention group
Group type: COMPARATOR
Intervention: Protein spread feeding (SD group, n=36).
Number of subjects: 66
Study 20602502 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective EVAR
Number of subjects: 756
Study 17692577 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 19
Study 17692577 — intervention group
Group type: COMPARATOR
Intervention: Bedtime NPH insulin
Number of subjects: 19
Study 16821426 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (up to 50 mg daily)
Number of subjects: 35
Study 16821426 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (up to 15 mg daily)
Number of subjects: 35
Study 16821426 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atenolol and midodrine
Number of subjects: 35
Study 16821426 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol, Midodrine, and their combination
Number of subjects: 35
Study 15228175 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Parent-Child Interaction Therapy (STD)
Number of subjects: 54
Study 15228175 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated Parent-Child Interaction Therapy (ABB)
Number of subjects: 54
Study 15228175 — intervention group
Group type: COMPARATOR
Intervention: No-treatment waitlist control group (WL)
Number of subjects: 54
Study 11508685 — intervention group
Group type: EXPERIMENTAL
Intervention: Aboral pouch
Number of subjects: 40
Study 11508685 — intervention group
Group type: COMPARATOR
Intervention: Simple Roux-en-Y reconstruction
Number of subjects: 40
Study 9282240 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbine spirometer (TS)
Number of subjects: 275
Study 9282240 — intervention group
Group type: COMPARATOR
Intervention: Bell spirometer (BS)
Number of subjects: 275
Study 7962933 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified buried vertical mattress suture technique
Number of subjects: 100
Study 7962933 — intervention group
Group type: COMPARATOR
Intervention: Conventional bi-layered closure technique
Number of subjects: 100
Study 2852792 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus vaccine (MMU-18006)
Number of subjects: 40
Study 29744871 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater occipital nerve (GON) blockade with bupivacaine
Number of subjects: 60
Study 29744871 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) dexketoprofen and metoclopramide
Number of subjects: 60
Study 29744871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline injection into the GON area)
Number of subjects: 60
Study 26899880 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfers (UCT)
Number of subjects: 4043
Study 26899880 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfers (CCT)
Number of subjects: 4043
Study 26899880 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 4043
Study 24283391 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Group 2)
Number of subjects: 200
Study 24283391 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Group 4)
Number of subjects: 200
Study 22257443 — intervention group
Group type: EXPERIMENTAL
Intervention: Polite yawning technique (PYT)
Number of subjects: 200
Study 22257443 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-laryngectomised patients)
Number of subjects: 200
Study 20042446 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg morphine
Number of subjects: 54
Study 20042446 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 54
Study 18657945 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session manual-guided spiritual guidance (SG) intervention during and after inpatient treatment
Number of subjects: 140
Study 18657945 — intervention group
Group type: COMPARATOR
Intervention: Spiritual direction (SG)
Number of subjects: 140
Study 18657945 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 140
Study 15945557 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (4-week program including postures and breath work)
Number of subjects: 62
Study 15945557 — intervention group
Group type: COMPARATOR
Intervention: Stretching control condition
Number of subjects: 62
Study 15945557 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 62
Study 12567365 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact normothermic wound therapy (Warm‐UP; Augustine Medical Inc.) applied for 1 hour 3 times daily until healing or 12 weeks.
Number of subjects: 20
Study 12567365 — intervention group
Group type: COMPARATOR
Intervention: Standard care (saline‐moistened gauze applied once a day).
Number of subjects: 20
Study 10551582 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg rapacuronium
Number of subjects: 336
Study 10551582 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg/kg succinylcholine
Number of subjects: 336
Study 8546143 — intervention group
Group type: EXPERIMENTAL
Intervention: PD Plus
Number of subjects: 7
Study 8546143 — intervention group
Group type: COMPARATOR
Intervention: CAPD
Number of subjects: 7
Study 1858703 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg valine.kg body wt‐1.d‐1 with 80 mg leucine.kg‐1.d‐1
Number of subjects: 6
Study 1858703 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg valine.kg body wt‐1.d‐1 with 40 mg leucine.kg‐1.d‐1
Number of subjects: 6
Study 1858703 — intervention group
Group type: COMPARATOR
Intervention: 10 mg valine.kg‐1.d‐1
Number of subjects: 6
Study 6863097 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 12
Study 6863097 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg/day)
Number of subjects: 12
Study 6863097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6863097 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (7 mg)
Number of subjects: 12
Study 29053410 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose exercise (8 kcal/kg of body weight per week)
Number of subjects: 49
Study 29053410 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose exercise (14 kcal/kg of body weight per week)
Number of subjects: 49
Study 29053410 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (both doses)
Number of subjects: 49
Study 29053410 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher VO2peak levels at baseline
Number of subjects: 49
Study 29553096 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous respiration (SP)
Number of subjects: 0
Study 29553096 — intervention group
Group type: COMPARATOR
Intervention: Controlled ventilation with muscle relaxants (MR)
Number of subjects: 0
Study 26598423 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 45 mg per day
Number of subjects: 21
Study 26598423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 26562086 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic Child Therapy (PaCT); approximately 20 psychotherapy sessions in various settings (parent-child, child-alone, parent-alone).
Number of subjects: 30
Study 26562086 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no intervention during the waitlist period).
Number of subjects: 30
Study 26562086 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent, child, and teacher reports.
Number of subjects: 30
Study 22297706 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative model of birth (AMB)
Number of subjects: 199
Study 22297706 — intervention group
Group type: COMPARATOR
Intervention: Traditional model of birth (TMB)
Number of subjects: 199
Study 19671217 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (1 mA current strength, five treatment sessions, active or sham, given on alternate days)
Number of subjects: 40
Study 19671217 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study 18606420 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg daily for 14 days
Number of subjects: 36
Study 18606420 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily for 14 days
Number of subjects: 36
Study 18606420 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 75 mg daily for 14 days (in CHD patients)
Number of subjects: 36
Study 15692973 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 279
Study 15692973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 11994884 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 43
Study 11994884 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no case management)
Number of subjects: 43
Study 10509953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with ascites
Number of subjects: 98
Study 10509953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients
Number of subjects: 98
Study 7852133 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 2.5 mg, 5.0 mg, and 10.0 mg tablets three times a day for 12 weeks (dose-titration study)
Number of subjects: 369
Study 7852133 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 5.0 mg and 10.0 mg tablets three times a day for 12 weeks (fixed-dose study)
Number of subjects: 369
Study 7852133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (fixed-dose study)
Number of subjects: 369
Study 7852133 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (all dosages)
Number of subjects: 369
Study 1777377 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg)
Number of subjects: 32
Study 1777377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 6743640 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) diet
Number of subjects: 0
Study 6743640 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-fat (MF) diet
Number of subjects: 0
Study 30060149 — intervention group
Group type: EXPERIMENTAL
Intervention: Leader Adolescents in Transcultural Health Education (LATES) Project
Number of subjects: 100
Study 30060149 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 30405296 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired homocysteine metabolism group (IHM, n=30)
Number of subjects: 40
Study 30405296 — intervention group
Group type: COMPARATOR
Intervention: Normal homocysteine metabolism group (NHM, n=10)
Number of subjects: 40
Study 26953629 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPT (once-daily extended-release tacrolimus tablets)
Number of subjects: 861
Study 26953629 — intervention group
Group type: COMPARATOR
Intervention: Tac BID (twice-daily tacrolimus capsules)
Number of subjects: 861
Study 26953629 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPT
Number of subjects: 861
Study 26953629 — intervention group
Group type: COMPARATOR
Intervention: Tac BID
Number of subjects: 861
Study 24300782 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatropin (0.03 mg/kg/day)
Number of subjects: 19
Study 24300782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 23302453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track surgery
Number of subjects: 70
Study 23302453 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 70
Study 20226447 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal support with micronized progesterone (group IIb)
Number of subjects: 9
Study 20226447 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal support with progesterone plus 17β-estradiol (group IIc)
Number of subjects: 9
Study 20226447 — intervention group
Group type: COMPARATOR
Intervention: No luteal phase support (group IIa)
Number of subjects: 9
Study 20226447 — intervention group
Group type: COMPARATOR
Intervention: Endometrial biopsies on the day of oocyte retrieval (group I)
Number of subjects: 9
Study 21512661 — intervention group
Group type: EXPERIMENTAL
Intervention: (131)I treatment
Number of subjects: 156
Study 21512661 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid volume
Number of subjects: 156
Study 16191752 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 36
Study 16191752 — intervention group
Group type: COMPARATOR
Intervention: Bupropion SR
Number of subjects: 36
Study 12030955 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential fatty acids (gamma-linolenic acid 1.6 g, eicosapentaenoic acid 270 mg, docosahexaenoic acid 45 mg per day)
Number of subjects: 63
Study 12030955 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sunflower oil 500 mg/day)
Number of subjects: 63
Study 9570606 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine in 0.75% glucose with 0.125% phenylephrine at the L2‐L3 interspace
Number of subjects: 120
Study 9570606 — intervention group
Group type: COMPARATOR
Intervention: 0.5% tetracaine in 0.75% glucose with 0.125% phenylephrine at the L3‐L4 interspace
Number of subjects: 120
Study 9570606 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine in 7.5% glucose with 0.125% phenylephrine at the L3‐L4 interspace
Number of subjects: 120
Study 8041539 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at PC‐6 point
Number of subjects: 60
Study 8041539 — intervention group
Group type: COMPARATOR
Intervention: Sham control (placebo point)
Number of subjects: 60
Study 8041539 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Acupressure and Sham)
Number of subjects: 60
Study 3051788 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy with pyloroplasty
Number of subjects: 78
Study 3051788 — intervention group
Group type: COMPARATOR
Intervention: Selective proximal vagotomy without pyloroplasty
Number of subjects: 78
Study 31884877 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional, mature arteriovenous fistulas (Group M)
Number of subjects: 52
Study 31884877 — intervention group
Group type: COMPARATOR
Intervention: Functional, non-mature arteriovenous fistulas (Group N)
Number of subjects: 52
Study 31884877 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results for both groups
Number of subjects: 52
Study 31884877 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline diameter of cephalic vein
Number of subjects: 52
Study 29923478 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 8-session worry intervention group (n = 7)
Number of subjects: 13
Study 29923478 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (n = 6)
Number of subjects: 13
Study 27517654 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (20mg loading dose, followed by 5mg maintenance dose daily)
Number of subjects: 76
Study 27517654 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300mg loading dose, followed by 75mg maintenance dose daily)
Number of subjects: 76
Study 25703448 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-exercise program
Number of subjects: 340
Study 25703448 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-exercise program (subgroup analysis)
Number of subjects: 340
Study 25703448 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 340
Study 24386859 — intervention group
Group type: COMPARATOR
Intervention: Control group (prepuce of phimosis children and urethra of penile carcinoma patients)
Number of subjects: 50
Study 19802508 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg
Number of subjects: 233
Study 18156455 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux membrane A (specific composition not detailed)
Number of subjects: 0
Study 18156455 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux membrane B (specific composition not detailed)
Number of subjects: 0
Study 18156455 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux membrane A
Number of subjects: 0
Study 18156455 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux membrane B
Number of subjects: 0
Study 18156455 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux membranes (general)
Number of subjects: 0
Study 15716709 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pressor therapy (initiated ≤ 12 hours from stroke onset)
Number of subjects: 2050
Study 15716709 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressor therapy (started ≤ 24 hours post-ictus)
Number of subjects: 2050
Study 15716709 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy (both pressor and depressor)
Number of subjects: 2050
Study 12949357 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 different foods with the same glycemic load as one slice of white bread
Number of subjects: 10
Study 12949357 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise increases in glycemic load (one, two, three, four, and six slices of bread)
Number of subjects: 10
Study 10733109 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (stimulator turned on)
Number of subjects: 2
Study 10733109 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (stimulator turned off)
Number of subjects: 2
Study 9275461 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg mifepristone daily
Number of subjects: 43
Study 9275461 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg mifepristone daily
Number of subjects: 43
Study 1636468 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Beverage
Number of subjects: 48
Study 1636468 — intervention group
Group type: COMPARATOR
Intervention: Lemonade Beverage
Number of subjects: 48
Study 1636468 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Risk Imagery
Number of subjects: 48
Study 1636468 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Risk Imagery
Number of subjects: 48
Study 1636468 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol/High-Risk Imagery
Number of subjects: 48
Study 6148991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg thrice daily
Number of subjects: 15
Study 6148991 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg daily
Number of subjects: 15
Study 31070712 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA enteral feeds (∼1% total fatty acids)
Number of subjects: 657
Study 31070712 — intervention group
Group type: COMPARATOR
Intervention: Standard-DHA enteral feeds (∼0.3% total fatty acids)
Number of subjects: 657
Study 30098152 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg/d)
Number of subjects: 606
Study 30098152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 27074067 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminectomy with posterolateral instrumented fusion
Number of subjects: 66
Study 27074067 — intervention group
Group type: COMPARATOR
Intervention: Decompressive laminectomy alone
Number of subjects: 66
Study 25014743 — intervention group
Group type: COMPARATOR
Intervention: Maternal feeding beliefs (measured at 4 months)
Number of subjects: 244
Study 25014743 — intervention group
Group type: COMPARATOR
Intervention: Maternal awareness of infant hunger and satiety cues (measured at 4 months)
Number of subjects: 244
Study 25014743 — intervention group
Group type: COMPARATOR
Intervention: Mothers' use of Pressure to eat (mediating factor)
Number of subjects: 244
Study 22768723 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0
Study 22768723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19836027 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines for management of acute gastroenteritis (AGE) training for pediatricians (group A)
Number of subjects: 1309
Study 19836027 — intervention group
Group type: COMPARATOR
Intervention: No specific training in guidelines for management of acute gastroenteritis (group B)
Number of subjects: 1309
Study 17827963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Fluor Protector)
Number of subjects: 273
Study 17827963 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 273
Study 16119035 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD (400 microg/day)
Number of subjects: 100
Study 16119035 — intervention group
Group type: COMPARATOR
Intervention: FP (250 microg/day)
Number of subjects: 100
Study 12495258 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium skim milk enriched with magnesium (milk group)
Number of subjects: 50
Study 12495258 — intervention group
Group type: COMPARATOR
Intervention: Apple drink (apple group)
Number of subjects: 50
Study 9817150 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial biopsies with multiple measurements of reticular basement membrane (RBM) thickness
Number of subjects: 18
Study 9817150 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial biopsies with counts of inflammatory cells
Number of subjects: 18
Study 7759173 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dosing of methadone
Number of subjects: 45
Study 7759173 — intervention group
Group type: COMPARATOR
Intervention: Twice daily dosing of methadone
Number of subjects: 45
Study 2655847 — intervention group
Group type: EXPERIMENTAL
Intervention: New pacemakers
Number of subjects: 70
Study 2655847 — intervention group
Group type: COMPARATOR
Intervention: Refurbished pacemakers
Number of subjects: 70
Study 400806 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg dapsone daily
Number of subjects: 0
Study 400806 — intervention group
Group type: COMPARATOR
Intervention: 100 mg dapsone and 600 mg rifampicin daily for 6 months
Number of subjects: 0
Study 31324343 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab
Number of subjects: 0
Study 31324343 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 28114723 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle endurance (RME) training for 8 weeks using an RME training device.
Number of subjects: 22
Study 28114723 — intervention group
Group type: COMPARATOR
Intervention: Standard chest physiotherapy (control) for 8 weeks.
Number of subjects: 22